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Abstract
Background: Despite international guidelines describing psychotherapy as first choice for people with personality
disorders (PDs), well-designed research on the effectiveness and cost-effectiveness of psychotherapy for PD is
scarce. Schema therapy (ST) is a specific form of psychological treatment that proved to be effective for borderline
PD. Randomized controlled studies on the effectiveness of ST for other PDs are lacking. Another not yet tested
new specialized treatment is Clarification Oriented Psychotherapy (COP). The aim of this project is to perform an
effectiveness study as well as an economic evaluation study (cost effectiveness as well as cost-utility) comparing ST
versus COP versus treatment as usual (TAU). In this study, we focus on avoidant, dependent, obsessive-compulsive,
paranoid, histrionic and narcissistic PD.
Methods/Design: In a multicentered randomized controlled trial, ST, and COP as an extra experimental condition,
are compared to TAU. Minimal 300 patients are recruited in 12 mental health institutes throughout the
Netherlands, and receive an extensive screening prior to enrolment in the study. When eligible, they are randomly
assigned to one of the intervention groups. An economic evaluation and a qualitative research study on patient
and therapist perspectives on ST are embedded in this trial. Outcome assessments (both for clinical effectiveness
and economic evaluation) take place at 6,12,18,24 and 36 months after start of treatment. Primary outcome is
recovery from PD; secondary measures include general psychopathological complaints, social functioning and
quality of life. Data for the cost-effectiveness and cost-utility analyses are collected by using a retrospective cost
interview. Information on patient and therapist perspectives is gathered using in-depth interviews and focus
groups, and focuses on possible helpful and impeding aspects of ST.
Discussion: This trial is the first to compare ST and COP head-to-head with TAU for people with a cluster C,
paranoid, histrionic and/or narcissistic PD. By combining clinical effectiveness data with an economic evaluation
and with direct information from primary stakeholders, this trial offers a complete and thorough view on ST as a
contribution to the improvement of treatment for this PD patient group.
Trial registration: Netherlands Trial Register (NTR): NTR566
Background
Personality disorders (PDs) are characterized by an
enduring, pervasive and pathological pattern of thoughts,
feeling and behavior expressed in a dysfunctional and
inappropriate manner, which is deviant from societal
norms. In the DSM-IV, personality disorders are grouped
into 3 clusters: the ‘odd, eccentric’ cluster A (paranoid,
schizotypal and schizoid PD), the ‘dramatic’ cluster B
(borderline, antisocial, histrionic and narcissistic PD),
and the ‘anxious’ cluster C (avoidant, dependent and
obsessive-compulsive PD) [1]. Despite the frequent appli-
cation of prolonged psychotherapy for people with per-
sonality disorders, controlled research into the clinical
and cost-effectiveness of psychotherapy is scarce [2]. This
is remarkable, given the substantial burden on patients
and society. Moreover, PDs are highly prevalent, as seen
in numbers ranging from 3 to 15% in community popula-
tion up to as high as 80-90% in secondary health care
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any medium, provided the original work is properly cited.settings [3-6]. PD-patients show chronic dysfunctions on
social and interpersonal level [7-10] and experience sub-
stantial impairment in work and basic self-care [11], lead-
ing to an enormous negative impact on the patient’s life
and the life of his/her close relatives. Furthermore, PDs
and personality-related factors play a key role in the
development and progress of other mental disorders, as
demonstrated in numerous cross-sectional and prospec-
tive studies [12-16].
Apart from patients, also society bears the costs of
chronic personality pathology. Factors attributing to
these notable costs are increased health care utilization,
productivity losses, and unstable employment through-
out the lifespan [17,18]. A recent study showed that the
costs of untreated PDs in the Netherlands are substan-
tially higher than those of other psychopathology like
depression or generalized anxiety disorder [19].
The evidence on treatment effectiveness for PDs that
exists so far is mostly restricted to borderline PD (BPD)
[20]. Several reviews report large effect sizes of specia-
lized psychological treatments for all PDs in general [21]
and specifically for cluster-C [22]. However, it should be
noted that most studies into treatment of non-BPD PDs
are of questionable methodological quality and show
conflicting results. A few RCTs focused on cluster-C
PDs. Emmelkamp et al. [23] showed greater improve-
ment in cognitive over psychodynamic psychotherapy for
Avoidant PD, while Svartberg, Stiles & Seltzer [24] found
these treatment forms to be equally effective for Cluster
C PDs. Another study [25] comparing manualized versus
non-manualized dynamic psychotherapy showed equal
decreases in the severity of PD symptoms, but both treat-
ment conditions failed to reduce psychiatric symptoms to
a ‘healthy’ level at post-test. Inconsistent findings also
appear when focusing on different treatment modalities
instead of different theoretical frameworks for cluster C.
Recent evidence suggests that outpatient psychotherapy
is equally effective as day treatment [26], while a natura-
listic study [27] showed only modest improvement for
outpatient therapy following day treatment in which con-
siderable progress was made. Bartak et al. [28] compared
different treatment modalities for cluster C in a multi-
center non-experimental study in the Netherlands, and
results favored short-term inpatient treatment over other
treatment modalities. On top of these contradictory find-
ings, studies on treatment effectiveness involving cluster
C are often difficult to interpret because this group of
PDs is mostly not the main research focus but partly
allowed as comorbid psychopathology (e.g. [29,30]).
Methodologically sound scientific investigation of treat-
ment effectiveness for paranoid, histrionic and narcissis-
tic PD hardly exists [31-33].
In a budget-constrained society, other important
aspects in the evaluation of a new treatment form are
costs and benefits of treatment. Unfortunately, for this
patient group the same paucity of controlled cost-effec-
tiveness studies is seen as with clinical effectiveness. The
few studies that suggest cost-effectiveness often are not
based on formal and well-prepared cost analyses [34].
An exception herein is an economic evaluation study
alongside the Dutch non-experimental study mentioned
before, in which cost-effectiveness of different treatment
modalities for both cluster B and C PDs is assessed
[35,36]. Results show that optimal treatment choice
depends on what threshold is considered acceptable.
Although this research gro u pe x e c u t e dp i o n e e r i n g
research in economic evaluations for non-BPD patient
groups, findings are difficult to interpret because of dif-
ferent focus (modalities instead of theoretical frame-
work) and non-randomization of patients.
Schema therapy (ST) gained a lot of attention the past
decade as a promising treatment for PDs. Clinical effec-
tiveness is shown for borderline PD both in an extensive
RCT (comparing ST head-to-head with Transference
Focused Psychotherapy (TFP) [37]) and in a Dutch
implementation study [38]. Also in group format ST
showed positive results for borderline PD [39]. The first
RCT mentioned demonstrated ST to be less costly and
more effective than TFP, so preferable in terms of cost-
effectiveness [40].
Because the aforementioned shortcomings, the need for
properly designed studies of psychological interventions
for non-Borderline PDs is pressing [33,41]. This is espe-
cially important as psychological treatment is considered
to be the treatment of choice for these disorders [34].
Despite some evidence for the effectiveness of ST techni-
ques for PDs other than borderline [42], properly designed
effectiveness and economic evaluation studies comparing
ST with other psychological treatments for non-borderline
PDs are lacking. The main objective of this study is to
evaluate the clinical and cost effectiveness of ST for a
group of 6 PDs: avoidant, dependent, obsessive-compul-
sive, paranoid, histrionic and narcissistic PDs. Other PDs
(borderline, antisocial, schizotypal and schizoid) are
excluded as they are deemed to require highly specialized
treatment protocols and higher dosage of treatment. In
this study a treatment protocol of 50 ST-sessions is com-
p a r e dt ot r e a t m e n ta su s u a l( T A U ) .T oa s s e s st ow h a t
degree a possible positive effect of ST is the result of the
effects of a new specialized and promising treatment, we
add the comparison of TAU with another specialized
treatment, clarification oriented psychotherapy (COP), a
form of client centered therapy developed for PDs [43], to
the design. Apart from the clinical effect study and eco-
nomic analysis, in a qualitative research part patients and
therapists are asked to provide insight in helpful and not
helpful aspects of the ST protocol. By collecting input
from direct users, valuable information is obtained to
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mary stakeholders.
The following research questions are defined:
Effectiveness study
How do ST and COP compare to TAU, in terms of
recovery from PD-diagnosis, reduction of psycho-
pathological symptoms and improvement of quality
of life?
Are these new treatments better in retaining patients
in therapy than TAU?
Economic evaluation
From a societal perspective, are ST and COP prefer-
able to TAU in terms of costs, effects and utilities?
Patient and therapist perspectives
What do patients and therapists believe to be helpful
and not helpful factors in the ST protocol?
Based on the superiority of ST found in previous
research, we hypothesize that (a) ST shows greater
clinical improvement than TAU, and (b) seen from a
societal perspective, ST is more cost effective in
terms of costs and utilities. Similarly, we test
whether another specialized treatment of PD, COP,
is superior to TAU in these respects.
Methods
This trial includes a clinical effectiveness study, an eco-
nomic evaluation and a qualitative research part regard-
ing patient and therapist perspectives on ST.
Clinical effect study
Design
The study is a multicentered randomized controlled trial
(RCT), in which patients are assigned to either ST or
TAU, while in 3 centers COP is added as a third treat-
ment condition. In Figure 1, information on patient flow,
screening procedures and intermittent assessments is
graphically shown. The research protocol is approved by
the Medical Ethical Committee of Maastricht University/
University Hospital Maastricht and by local committees
in participating centers.
Recruitment
Patients are recruited in 12 mental health care institutes
throughout the Netherlands (Geestgronden Noord-Hol-
land, GGZ Oost-Brabant, GGZ Nijmegen, Mediant
Enschede, Mondriaan Zorggroep Heerlen, Reinier van
Arkelgroep Den Bosch, Riagg Maastricht, Riagg Rijnmond,
Riagg Zuid Roermond, Rivierduinen Leiden, Symfora
Hilversum, and UMC Radboud Nijmegen). They are
referred to the study either during intake (i.e. at first con-
tact with mental health care institute), after having
received previous care that failed to reduce their PD pro-
blems, or by clinicians treating these patients for chronic
problems. After patients receive both written and oral
information and signed informed consent, in- and exclu-
sion criteria are checked.
Participants
P a t i e n t sa r ee l i g i b l ei ft h e yh a v eo n eo rm o r ed i a g n o s e s
of avoidant, dependent, obsessive-compulsive, paranoid,
histrionic and/or narcissistic PD. This PD has to be the
principal diagnosis, according to both patient and clini-
cal staff, and patients should request help for PD-related
problems. Further, inclusion criteria are age 18-65 and
not having problems with Dutch language (talking,
understanding, reading and writing). In- and exclusion
criteria are described in Figure 1.
At baseline clinical diagnoses are assessed with the
Dutch version of the Structured Clinical Interviews
(SCID) for DSM-IV Axis-I and Axis-II disorders ([44-47]
and executed by extensively trained clinicians at local
sites). For clients having more than 1 PD diagnosis, main
diagnosis is determined by the interviewer or -if missing-
by 2 raters (LB & AA) after clinical judgment and taking
into account self-reported reason for seeking help.
Sample size
Power calculations for ST and TAU are based on the
results from the BPD trial comparing ST and Transfer-
ence Focused Psychotherapy (TFP) [37]. The study is
powered to detect a difference between ST and TAU in
proportion recovered patients of 46 vs. 24% (OR = 2.70).
With alpha = .05 (2-tailed), n = 100 per condition yields
a power of 90%. To account for possible dropouts (ca.
18% expected based on [48]), 125 patients are needed per
condition. With the planned sample sizes (ST = 125;
TAU = 125; COP = 50) power is 78% (70% after dropout)
to detect a similar difference between COP and TAU.
Randomization and procedure
Following inclusion in this trial, patients complete an
extensive baseline assessment prior to randomization.
An independent statistician generated a computerized
randomization list using Adaptive Biased Urn Randomi-
zation for small strata [49], which keeps randomization
unpredictable up to and including the last patient on
each site, while keeping the group sizes at each site in
good balance. A study-independent central research
assistant checks in/exclusion criteria, and reads the next
available treatment condition per center from this ran-
domization list, and passes it on to local staff by e-mail.
Once allocated, further matching between patient and
therapist is allowed and performed by local teams (ST &
COP) and regular intake staff (TAU).
After start of treatment, assessments occur every 6
months during the first 2 years, followed by a follow up
assessment 3 years after start of therapy. All assessments
are executed by independent research assistants at local
sites, except for SCID-interviews which are performed by
trained clinicians at local sites during inclusion period and
by trained independent interviewers at follow-up. In
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(administered on PC), a cost-interview and a computer
task. When study dropout is imminent due to unwilling-
ness to come to the center for assessments, questionnaires
could be filled out at home. In these cases, cost interviews
are administered by telephone. Given the nature of our
study, blinding of participants and research assistants is
not possible. However, the primary outcome is assessed by
independent central interviewers, blind for condition. To
optimize similarity in assessments, research assistants
receive a one-day training regarding the study protocol
given by members of the central research committee of
Maastricht University, discuss process in regular telepho-
nic meetings and use an extensive standardized study
protocol.
Treatments
All sites offer ST and TAU. In 3 centers a third treatment
condition (COP) is added. In this way, a standardized and
highly specialized outpatie n tt r e a t m e n ti sa d d e da sa n
extra control. Because of restricted COP-therapist capa-
city at most sites, COP is only offered at 3 sites.
ST and COP are characterized by the following com-
monalities: therapists receive extensive expert-training at
study start, yearly national supervision and weekly peer-
supervision at local sites; both are outpatient treatments,
(initially) delivered in weekly sessions; additional psycho-
logical treatment with focus on personality pathology is
not allowed; and psychopharmacological treatment is
permitted, but only on clinical indication according to an
independent psychiatrist.
Schema therapy (ST) Schema therapy (ST) was originally
developed for people with severe personality pathology
and combines experiential, cognitive-behavioral, psychody-
namic and interpersonal techniques [50]. The concept of
schema modes is central in current ST [51]. ST aims at
reducing maladaptive modes and strengthening the
healthy adult mode. Arntz & Young created a theoretical
model containing the most prevalent modes for the 6 PDs
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Figure 1 : Flow chart study design. ST = schema therapy, TAU = treatment as usual, COP = clarification oriented psychotherapy
Figure 1 Flow chart study design. ST = schema therapy, TAU = treatment as usual, COP = clarification oriented psychotherapy.
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protocol is developed with 40 weekly sessions in year 1
and 10 booster sessions in year 2. The treatment protocol
is naturalistic in the sense that, apart from the framework
directing treatment focus throughout sessions, therapists
do not have a session-to session detailed treatment
manual.
At start of treatment, a maximum of 6 sessions is
spent on introduction, patient history and case concep-
tualization. During the first half year, focus mainly lies
on in-session child, parent and coping modes with
emphasis on processing childhood experiences through
imagery rescripting and other experiential techniques. In
the second half year, current life experiences and active
changing of behavior are targeted. Booster sessions in
the second year could be spread according to the wishes
of therapist and patient, and are intended to maintain
newly acquainted healthy behavior, recognize possible
pitfalls and prevent relapse.
Clarification oriented psychotherapy (COP) COP is a
treatment rooted in client centered therapy (CCT),
developed by Sachse [43,54]. It was designed to clarify
and restructure dysfunctional cognitive-affective sche-
mas focusing strongly on interpersonal behavior and
problems. COP also offers specific techniques in the
treatment of PDs. In this model, PDs are conceptualized
on a dimension ranging from slight characteristics of a
PD (not diagnosed by DSM-IV), to pathological and
extreme interaction patterns. Based on unmet social
needs in childhood or youth, interaction patterns are
developed which may have been functional at the time,
but are not anymore. According to Sachse, PD-charac-
teristics occur at 3 levels: (1) the level of authentic
needs: appreciation, importance for (to) others, reliabil-
ity of relationships, solidarity of relationships, autonomy
and boundaries (2) the level of schemas, which are
assumptions about the self and others, and (3) the level
of play, which is highly automated and not transparent,
manipulative and controlling. Whilst this play behavior
is intended to get needs fulfilled, this often doesn’t
work. The goal of treatment is to enlarge the authentic
being of patients, by satisfying authentic needs, gaining
insight in schemas and reducing play behavior. Thera-
peutic techniques to achieve this are being complemen-
tary with authentic needs, uncomplimentary with play
behavior, confronting with play behavior and clarifying
and restructuring rigid schemas. Just like the first year
in the ST protocol, COP is offered weekly to patients.
Contrary to the ST protocol, COP is open ended with-
out a strict number of treatment sessions, as this fits
best with its CCT nature.
Treatment as usual (TAU) In this treatment condition,
treatment is whatever care (except ST/COP) a patient
would receive if the study would not take place. Generally
TAU is expected to follow the multidisciplinary clinical
guidelines for PDs in the Netherlands [55]. When allo-
cated to TAU condition, the regular intake staffs at local
sites indicate the specific treatment format for that patient.
Thus, the matching of patient to type of regular treatment
by the responsible clinicians at the site is part of TAU. In
this way, TAU is optimized and mimics usual practice.
Therapists, training, and treatment integrity check
ST and COP therapists received an extensive 4 day
expert-training before study start. Due to one center
withdrawing participation after training but before
recruiting patients, two extra sites were added to com-
pensate, and extra therapists (also from the first group of
centers) were trained in ST in a second training. This
creates two ‘waves’ in the study (from now on referred to
as therapy cohorts). There are potentially important dif-
ferences between the two ST-trainings. The first cohort
was trained in a foreign language (English) and consisted
of 73 therapists, while the second cohort consisted of 20
therapists who were trained in their native language
(Dutch). Training in the first cohort consisted mainly of
lectures and video demonstrations, whereas the second
training was much more structured with short instruc-
tions, life demonstration, and compulsory role-plays for
the participants to train the main therapeutic techniques.
Therapists are uniquely assigned to one of the treat-
ment conditions to prevent contamination, with the
exception of 6 ST and 3 COP therapists who also act as
a group-therapist in TAU. This exception is allowed as
these therapists have non-ST/COP co-therapists that
help them to stick to the non-ST/COP format of these
group therapies.
Adherence to treatment protocol and absence of tech-
niques and elements from contrasting treatments is
checked. Except for group treatment in TAU (where
non-study participants do not give consent to record ses-
sions), all treatment sessions are audio taped. Eventually,
3 sessions per patient are randomly selected for evalua-
tion; 1 from the first 5 weeks, 1 from the first half year
and 1 from the second half year of treatment. An instru-
ment to measure treatment adherence is developed based
on the ST Therapy Adherence and Competence Scale for
B P D[ 5 6 ] ,t h eC o l l a b o r a t i v eS tudy Psychotherapy Rating
Scale 6 (CSPRS-6);[57,58], and elaborated consultation
with ST- and COP-experts.
Economic evaluation study
The economic evaluation is performed from a societal
perspective, and involves a combination of a cost-effec-
tiveness analysis (CEA) and a cost-utility analysis (CUA).
In a CEA effects are presented in clinical outcomes (in
our study recovery of diagnosis). The primary outcome
measures for the cost-utility analysis are QALYs, based
on the EuroQol utility scores [59,60]. Comparing ST and
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Effectiveness Ratios (ICERs) that express the incremental
costs per recovered patient and per QALY gained. The
net monetary benefit (NMB) is feasible to compare three
treatments in one analysis. The NMB is calculated by
multiplying the increase in effectiveness by the amount
decision-makers are willing to pay for one extra unit of
effect, minus the increase in costs. In the base-case ana-
lyses, a monetary threshold of € 20,000 is used [40].
For the identification of costs, a division is made into
healthcare costs and productivity losses. Because it is
very hard to make a clear distinction between PD-
related and non-PD-related costs, all costs are taken
into account. Costs are divided into (1) main interven-
tion costs in participating health care center (i.e. treat-
ment patients were randomly assigned to) (2) other
mental health care received, (3) health care costs, con-
taining medication (divided in prescribed and over the
counter medication), general practitioner, emergency
care, outpatient consults in general hospital, and admis-
sions to general hospital, and (4) productivity costs
(further divided in costs due to PDs and costs due to
other complaints).
Patient and therapist perspectives
We aim to identify specific helpful and not helpful
aspects of the ST protocol used in this study. This infor-
mation is derived by using qualitative research methods
with primary stakeholders (patients and therapists). A
selection of ST patients and therapists is asked to parti-
cipate in this qualitative study, as many as necessary
until saturation appears (when no more information is
added and replication occurs). Patients receive semi
structured in-depth interviews in the early phases of
treatment (time point 1) and after completion of treat-
ment (time point 2). At time point 2, also patients who
dropped out of treatment are interviewed. Therapists
share their experiences in a focus group (structured
group session in which thoughts and views about certain
predefined ST topics are exchanged, led by a chairper-
son) at equal time points. Some main topics are: helpful
and harmful aspects of ST, the use of specific ST techni-
ques, therapeutic relationship, supervision and training
of therapists.
Patient interviews and therapist focus groups are
recorded and fully transcribed. All participants receive a
verbatim transcript and are asked to verify whether their
opinion is expressed correctly (member check).
Instruments
Instruments are used in the screening process, the clini-
cal effect study and the economic evaluation study. In
Table 1 an overview of all instruments per time point is
shown.
Primary outcome and PD-diagnosis
Structured clinical interview for personality disorders
(SCID-II)
Primary outcome is presence versus absence of PDs,
which is assessed with SCID-II-interviews at follow-up 3
years after start of treatment. Interviews are administered
by telephone after the follow up assessment at local sites
and executed by a group of independent raters blinded
for condition. Raters are trained in SCID interviews, and
inter rater reliability is assessed. Only those PD-modules
and criteria are assessed on which patients scored at
baseline and further all specific DSM-IV criteria on
which patient scored 4 or more on the 1–7s c a l eo ft h e
ADP-IV at follow up (when 3 or more criteria per PD
had a >4 score, the complete PD had to be assessed).
Each relevant PD-criterion has to be scored as absent
(score 1), questionable (score 2), or present (score 3) for
both the 6 months prior to FU, and the half year before
that. The sum of 3-scores points out whether sufficient
criteria are met for a specific PD-diagnosis. Previous stu-
dies found adequate to good inter-rater reliability for
SCID II interviews [61][62][63]. Recovery from diagnosis
as measured with SCID II is the primary outcome mea-
sure in this study. When patients do not exceed the mini-
mal number of criteria needed to obtain a diagnosis on
any of the 6 PDs under study, they are considered to be
recovered. Because of the lenience of this criterion, we
assess sensitivity by reanalyzing presence vs. absence of
subthreshold diagnoses (defined by meeting one PD-cri-
terion less than needed for a full diagnosis).
Secondary outcomes
Assessment of DSM-IV personality disorders ques-
tionnaire (ADP-IV)
At every intermediate and follow up assessment, PD-
pathology and associated distress are assessed with the
ADP-IV [64]. With this self-report questionnaire, DSM-
IV PD criteria are assessed. Patients have to indicate on a
7-point Likert scale to what degree PD criteria hold for
them, ranging from 1 (’not at all’)t o7( ’completely’), and
whether they experience distress from it (on a range
from 1-not at all to 3-definitely). Item construction of the
ADP-IV allows for both dimensional and categorical
diagnostic evaluation [65]. Adequate internal consistency,
validity and reliability were shown consistently in pre-
vious studies [65-67].
Structured clinical interview for axis I disorders
(SCID I)
SCID I is used both as screening and outcome instru-
m e n t .D u r i n gs c r e e n i n g ,S C I DI[ 4 4 , 4 6 ]i su s e dt oc h e c k
for Axis I diagnoses that might lead to exclusion (psycho-
sis, bipolar disorder, substance abuse). At follow up,
Axis-I diagnoses of mood and anxiety disorders (as the
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blind interviewers registering SCID II. SCID I proved to
have acceptable psychometric properties [61].
Global assessment of functioning scale (GAF) and
social and occupational functioning scale (SOFAS)
These 100-point scales are derived from DSM Axis V,
to assess global functioning & symptom severity (GAF)
and social functioning (SOFAS). Both scales are admi-
nistered by the research assistant at each measurement
after a semi-structured interview to elicit relevant infor-
mation. Lower scores indicate poorer functioning and
greater symptom severity. These scales have shown to
be a valid and reliable rating scale of global psycho-
pathology [68,69].
Symptom check list (SCL-90)
General psychopathological symptoms are assessed
with the SCL-90 [70]. This self-report inventory con-
tains 90 items that have to be scored on a 5-point Likert
scale of distress, ranging from ‘not at all’ to ‘extremely’.
T h et o t a ls c o r ec a nb eu s e da sam e a s u r eo fg l o b a l
symptom severity. The SCL-90 has good psychometric
properties [71].
Work and social adjustment scale (WSAS)
The WSAS is a simple 5-item list used to assess gen-
eral impairment on several life domains like work,
household, social and private leisure, family and rela-
tionships [72]. Each item has to be scored on a range
from 0 to 8. Higher scores denote more disability. This
instrument proved to be reliable, valid and change-sensi-
tive in various patient populations [73].
Miskimins self goal other (MSGO)
The MSGO is a measure to assess discrepancy
between actual and ideal self-perception [74]. 30 person-
ality trait dimensions have to be scored on a 100 mm
visual analogue scale, for current and ideal self-percep-
tion respectively. Discrepancy scores are derived by
calculating the mean difference across items. The
MSGO has shown adequate psychometric properties in
previous studies [42,75].
World health organisation quality of life question-
naire (Whoqol-short)
Quality of life is assessed with a modified version of
the World Health Organisation Quality of Life Ques-
tionnaire. Patients have to self-report to what extent
they experience quality of life on several domains (phy-
sical, psychological, social relationships, environment,
positive feelings, negative feelings, self-esteem) [76,77].
Psychometric studies revealed the WHOQOL to be a
valid and reliable measure.
Euroqol-5D
The EuroQol is a standardized non-disease specific
instrument for describing and valuing health-related
quality of life. Next to the assessment of quality of life
on five health-state dimensions (mobility, self-care, usual
activity, pain/discomfort and anxiety/depression), the
EuroQol thermometer ranges someone’sc u r r e n th e a l t h
status between 0 and 100 [59]. For the cost-utility analy-
sis, the profiles resulting from the five health-state
dimensions can be converted into utilities based on the
social tariffs of the EuroQol, the so-called EQ-5D UK
value set [78]. Utilities refer to the preference for any
particular set of health outcomes and are generally indi-
cated by a number between 0 and 1. Utilities at different
time points are used to compute QALYs. A QALY com-
bines preferences for both length of survival and its
quality into one single measure.
Resource use
For the resources, a distinction is made between inter-
vention costs and other resource use. The number of
sessions and specific content of interventions are gath-
ered by local research assistants, while costs of all other
resources are measured by means of a structured cost
Table 1 Overview of instruments per time point
Screening Baseline 6 months 12 months 18 months 24 months 36 months
SCID II ￿ ￿
SCID I ￿ ￿
ADP-IV ￿ ￿ ￿￿￿￿
GAF ￿ ￿ ￿￿￿￿
SOFAS ￿ ￿ ￿￿￿￿
SCL-90 ￿ ￿ ￿￿￿￿
WSAS ￿ ￿ ￿￿￿￿
MSGO ￿ ￿ ￿￿￿￿
Whoqol-short version ￿ ￿ ￿￿￿￿
Euroqol-5D ￿ ￿ ￿￿￿￿
Cost interview ￿ ￿ ￿￿￿￿
SCID I = Structured Clinical Interview for Axis-I Disorders, SCID-II = Structured Clinical Interview for Axis-II Disorders, ADP-IV = Assessment of DSM-IV Personality
Disorders Questionnaire, GAF = Global Assessment of Functioning, SOFAS = Social and Occupational Functioning Scale, SCL-90 = Symptom Check List, WSAS =
Work and Social Adjustment Scale, MSGO = Miskimins Self Goal Other, Whoqol-short version = World Health Organization Quality of Life Questionnaire - short
version
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Page 7 of 12interview [79] at every assessment. In this interview,
patients are asked to specify work status and absentee-
ism, and they report the use of medication, GP visits
and contacts with different services. The cost interview
is retrospective in nature. For most questions a 3-month
recall period is used, except for costly admissions to
general or psychiatric hospitals and crisis services, in
which a 6 or 12 month recall period is used (for inter-
mittent and follow up assessments respectively).
Analyses
All analyses are planned to be carried out with SPSS
19.0 and MLWin 1.10, while bootstrap simulations are
done using Excel.
Clinical analyses
Data analyses are based on intention to treat analyses
(including all patients regardless of whether they drop
out from treatment or not), using all available data.
Intermittent missing data on item level are imputed by
mean values from previous and subsequent time points.
Primary outcome (recovery from PD diagnosis) and
dichotomous secondary outcome parameters (absence of
comorbid depression or anxiety disorder), are analyzed
with multilevel logistic regression. Continuous secondary
outcome parameters are analyzed with multilevel mixed
models. In these multilevel models center is treated as a
random factor (i.e., random intercepts and slopes (if
applicable)). If changes over time are mainly linear, lin-
ear trend in time is inspected; otherwise the time vari-
able is transformed to obtain a linear relationship.
When outcome parameters are not distributed normally,
appropriate transformations are used.
Predictors of outcome are incorporated in the ana-
lyses. To control for baseline severity a composite mea-
sure is constructed out of standardized baseline values
of: # axis-I disorders, # axis-II disorders, ADP-4 trait
sum score, ADP-4 distress sum score, SCL-90, GAF,
SOFAS, disability status (biographical variable). Being
new vs. ‘chronic’ patient is not associated with these
variables, neither with outcome, thus left out of consid-
eration. The severity-index is used as covariate in out-
come analyses. Since the difference between a more
passive and a more active, experiential-learning oriented
training is potentially very important for implementation
and for effectiveness of treatment, we include this vari-
able in the analyses to test for moderation, and to con-
trol for possible effects. For 2 sites, all ST therapists
were trained in the second cohort; therefore all TAU-
patients of these sites are their patients’ controls. For
other sites, a minority of ST-therapists was trained in
the second cohort, and control TAU patients are
selected per site by matching TAU-patients to the 2nd
cohort ST-therapists’ patients on the basis of 1st diagno-
sis, gender and age.
Given the strong positive effect of ST on treatment
retention found in earlier studies [37-39], dropout is
analyzed with both multilevel logistic regression and
survival analysis (to account for development over time).
To assess treatment integrity, a random selection of
audiotapes of treatment sessions is rated by trained
independent judges, blind for condition. A subset of
recordings is rerated to estimate inter rater reliability,
expressed with the intra class correlation coefficient
(ICC).
Economic evaluation
The economic analysis is also performed according to
the intention-to-treat principle. As mentioned before,
both a cost-effectiveness analysis CEA (expressing
effects as recovery of diagnosis) and cost-utility analysis
CUA (effects expressed as QALYs) are done.
For the valuation of cost prices, standard Dutch unit
prices are used [80] or-when unavailable- average tariffs.
Prescribed medication costs are based on the Dutch
Pharmacotherapeutic Compass [81]. Productivity costs
are calculated according to the human capital method
(total productivity costs are the product of total hours
lost with hourly wage), as this method is preferable in
patient groups with apparent disease-related work dis-
ability [82].
Costs are calculated by multiplying volumes with price
per cost item. All prices are expressed in Euros for the
year 2007 (since the majority of treatments started in
this year). If necessary, costs are indexed to the year
2007 by means of the consumer price indexes of the
Dutch Central Bureau of Statistics (CBS). Since the time
horizon of the study is 3 years, a discount of 4% per
year is applied.
Differences between experimental and control groups
in quality of life are analyzed with ANOVA or non-
parametric alternatives at the p < .05 significance level.
Because of the usually non-normal distribution of costs,
bootstrapping is used to calculate 95% confidence inter-
vals around costs.
For base-case analyses, primary outcome parameters
are proportion of recovered patients (CEA), and total
QALY gained during 3 years (CUA).
Uncertainty around costs and effects is dealt with by
performing several sensitivity analyses following base-case
analyses. Some sensitivity analyses are: analyzing only data
from study completers (patients who have complete data
sets at every intermittent assessment as well as follow up),
correcting for baseline costs and utilities, using Dutch [83]
instead of UK value set for QALYs.
Bootstrap simulations are used to estimate sample
uncertainty around the cost-effectiveness ratios and are
plotted in cost effectiveness planes, in which the posi-
tion of the bootstrapped cost-effectiveness pairs gives an
indication for possible superiority of one treatment over
Bamelis et al. BMC Public Health 2012, 12:75
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Page 8 of 12another. In a cost effectiveness acceptability curve
(CEAC), the probability of ST being superior across a
range of willingness to pay thresholds is plotted. Since
the maximum amount of money that society wants to
pay is unknown, the monetary threshold per QALY will
be varied between € 0 and € 80,000 [84].
Patient and therapists perspectives
Content analyses are executed on the verbatim tran-
scripts produced by interviews and focus groups. Recur-
ring themes and topics are labeled and clustered.
Discussion
Personality disorders (PDs) are complex mental health
problems associated with low levels of quality of life,
high health care and general society costs, and poor
prognosis. Psychological treatment is considered to be
the treatment of choice, but research into the clinical
and cost effectiveness is sparse and strongly focused on
borderline PD. The current study aims to study the
effectiveness of schema therapy (ST) compared to treat-
ment as usual (TAU) for 6 PDs not so often studied:
cluster-C (i.e. avoidant, dependent, obsessive-compul-
sive), paranoid, histrionic and narcissistic PD. As an
additional control another specialized treatment, clarifi-
cation oriented psychotherapy (COP), is added as a
third condition in 3 of the 12 participating centers.
Methodological considerations
For our study, a large group of patients and cooperation
with many different mental health institutes is necessary.
The large number of patients and centers included
makes generalizability to population level credible. Fol-
lowing a group of PD patients for a 3 year period in an
RCT design is unique in the field. Recommendations for
psychotherapy research for personality disorders [48] are
taken into account, such as: (a) long duration of treat-
m e n ta n df o l l o wu pm e a s u r e ment, giving the opportu-
nity to study core characterological change rather than
symptomatic change, (b) use of psychometrically sound
and well-known outcome measures, and (c) naturalistic
ST and COP protocols, resembling real clinical practice
better than tight and detailed manuals.
Several limitations and possible pitfalls should be
noted. First, due to time restrictions on the inclusion
period, the diagnostic profile of patients is mainly deter-
mined by the natural flow of patients at local sites. A
possibly uneven distribution between the 6 PDs under
study is a consequence of that, which might limit the
possibilities to draw conclusions on PDs with small
numbers. Second, comparing an experimental treatment
condition with treatment as usual sets boundaries to the
possibility to control for various potentially influencing
factors (e.g. uneven duration of treatment, frequency of
sessions, etc.). We try to overcome this by adding a sec-
ond experimental condition (COP). The choice for TAU
has merits and demerits. For relatively new treatments
such as ST a comparison to treatment as usual is a valu-
able first step: one would at least require that a new
treatment excels existing practice. TAU includes in our
study potentially many different treatments, which
reduces the kind of control experimental psychologists
would like to see (e.g., of factors like attention, fre-
quency, expectations, etc.). On the other hand, the
external validity of the control condition is increased,
and TAU is optimized by having clinicians making deci-
sions on what type of regular treatment to offer (e.g.,
see [85] for evidence that intakers can predict effective-
ness of psychodynamic therapy). Moreover, for cost-
effectiveness the comparison of a new treatment to
usual practice is the gold standard [86].
Another important problem potentially affecting the
q u a l i t yo ft h es t u d yi sc r e a t e db yt h eo r g a n i z a t i o n a l
scale of a trial in which so many parties (sites, patients,
therapists, coordinators, and research assistants) are
involved. The study’s scale and the limited financial
resources preclude the possibilities for continuous and
close monitoring and steering. During the trial,
researchers and centers need the capacity and flexibility
to overcome numerous problems, e.g. insufficient inclu-
sion, loss of participating centers/research assistants/
therapists and the enrolment of new ones, inadequate
execution of study protocol, etc. The large scale of the
study, at least for psychotherapy research, reduces possi-
bilities to intensively supervise and control treatment
delivery. In that sense, the present study is a true effec-
tiveness study, differing from highly controlled efficacy
studies.
As to the assessments, we choose for independent and
blinded interviewers for assessing the primary outcome.
Whilst this is a strong point, financial and logistic lim-
itations preclude that secondary interview outcomes and
the cost-interview are taken by blinded research assis-
tants. Lastly, the primary outcome is defined by absence
of PD at 3-yr follow-up, operationalized by not meeting
criteria for a PD on the SCID-II. This is a bit lenient
criterion, and therefore we assess sensitivity of results by
a reanalysis with a stricter criterion, that is the absence
of full and subthreshold PDs.
Conclusion
Schema therapy is gaining interest worldwide as a treat-
ment for personality disorders. However, its effective-
ness for most personality disorders is so far unknown.
T h i ss t u d yg i v e sau n i q u eo p p o r t u n i t yt of i l lt h i sg a po f
knowledge by combining clinical and cost effectiveness
analyses within a large group of PD patients.
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